产品名称: FITC标记的磷酸化乳腺癌易感基因1抗体
英文名称: Anti-Phospho-BRCA1 (Ser1466)/FITC
抗体货号: HZ-20442R-FITC
产品规格: 100ul
级    别: , , 分析纯, , 分析纯,
产品产地: 中国/上海
品牌商标: HZbscience
价    格: 2980元
抗原: Rabbit
抗原来源: Rabbit
抗体来源: Rabbit
应用范围: Flow-Cyt=1:50-200 ICC=1:50-200 IF=1:50-200
更新时间: 2019/4/23 16:15:00
详细资料:  实验方法技术资料
在线QQ: 我是2043711056,请问我有什么可以帮到您呢?




 Rabbit Anti-Phospho-BRCA1 (Ser1466)/FITC Conjugated antibody



英文名称 Anti-Phospho-BRCA1 (Ser1466)/FITC
中文名称 FITC标记的***酸化乳腺癌易感基因1抗体
别    名 BRCA1 (phospho S1466); BRCA1 (phospho Ser1466); p-BRCA1 (S1466); p-BRCA1 (Ser1466); p-BRCA1 (phospho S1466); BRCA1(Phospho-Ser1423); BRCA 1; BRCA1; BRCA1/BRCA2 containing complex subunit 1; BRCA1/BRCA2-containing complex, subunit 1; BRCA1_HUMAN; BRCAI; BRAC 1; BRCA 1; BRCC 1; BRCC1; Breast Cancer 1; Breast Cancer 1 Early Onset; Breast cancer type 1 susceptibility protein; Breast and ovarian cancer susceptibility protein 1; Breast Ovarian Cancer Susceptibility; IRIS; Papillary Serous Carcinoma Of The Peritoneum; PSCP; RING finger protein 53; BROVCA1; IRIS; PNCA4; PPP1R53; Protein phosphatase 1 regulatory subunit 53; RNF53; BAP1.  
规格价格 100ul/2980元 购买        大包装/询价
说 明 书 100ul  
产品类型 ***酸化抗体 
研究领域 肿瘤  细胞生物  信号转导  细胞凋亡  
抗体来源 Rabbit
克隆类型 Polyclonal
交叉反应 Human, Horse, 
产品应用 Flow-Cyt=1:50-200 ICC=1:50-200 IF=1:50-200  
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 208kDa
性    状 Lyophilized or Liquid
浓    度 2mg/1ml
免 疫 原 KLH conjugated synthetic peptide derived from human Phospho-BRCA1 (Ser1466)
亚    型 IgG
纯化方法 affinity purified by Protein A
储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
产品介绍 background:
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009].

E3 ubiquitin-protein ligase that specifically mediatesthe formation of 'Lys-6'-linked polyubiquitin chains and plays acentral role in DNA repair by facilitating cellular responses toDNA damage. It is unclear whether it also mediates the formation ofother types of polyubiquitin chains. The E3 ubiquitin-proteinligase activity is required for its tumor suppressor function. TheBRCA1-BARD1 heterodimer coordinates a diverse range of cellularpathways such as DNA damage repair, ubiquitination andtranscriptional regulation to maintain genomic stability. Regulatescentrosomal microtubule nucleation. Required for normal cell cycleprogression from G2 to mitosis. Required for appropriate cell cyclearrests after ionizing irradiation in both the S-phase and the G2phase of the cell cycle. Involved in transcriptional regulation ofP21 in response to DNA damage. Required for FANCD2 targeting tosites of DNA damage. May function as a transcriptional regulator.Inhibits lipid synthesis by binding to inactive phosphorylatedACACA and preventing its dephosphorylation. Contributes tohomologous recombination repair (HRR) via its direct interactionwith PALB2, fine-tunes recombinational repair partly through itsmodulatory role in the PALB2-dependent loading of BRCA2-RAD51repair machinery at DNA breaks. Component of the BRCA1-RBBP8complex which regulates CHEK1 activation and controls cell cycleG2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination ofRBBP8.

Heterodimer with BARD1. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Component of the BRCA1-A complex, at least composed of the BRCA1, BARD1, UIMC1/RAP80, FAM175A/Abraxas, BRCC3/BRCC36, BRE/BRCC45 and BABAM1/NBA1. Interacts (via BRCT domains) with FAM175A/Abraxas and RBBP8. Associates with RNA polymerase II holoenzyme. Interacts with SMC1A and COBRA1/NELFB. Interacts (via BRCT domains) with phosphorylated BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with DCLRE1C/Artemis and CLSPN. Interacts with H2AFX (phosphorylated on 'Ser-140'). Interacts with CHEK1 and CHEK2. Interacts with BRCC3. Interacts (via BRCT domains) with ACACA (phosphorylated); the interaction prevents dephosphorylation of ACACA. Interacts with AURKA. Interacts with UBXN1. Part of a trimeric complex containing BRCA1, BRCA2 and PALB2. Interacts with PALB2 and this interaction is essential for its function in HRR. Interacts with BRCA2 only in the presence of PALB2 which serves as the bridging protein.

Subcellular Location:
Cytoplasm; Nucleus. Localizes at sites of DNA damage at double-strand breaks (DSBs) and recruitment to DNA damage sites is mediated by the BRCA1-A complex.

Tissue Specificity:
Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines. 

Post-translational modifications:
Phosphorylation at Ser-308 by AURKA is required for normalcell cycle progression from G2 to mitosis. Phosphorylated inresponse to IR, UV, and various stimuli that cause checkpointactivation, probably by ATM or ATR. Phosphorylation at Ser-988 byCHEK2 regulates mitotic spindle assembly.
Autoubiquitinated, undergoes 'Lys-6'-linkedpolyubiquitination. 'Lys-6'-linked polyubiquitination does notpromote degradation.

Defects in BRCA1 are a cause of susceptibility to breastcancer (BC) [MIM:114480]. A common malignancy originating frombreast epithelial tissue. Breast neoplasms can be distinguished bytheir histologic pattern. Invasive ductal carcinoma is by far themost common type. Breast cancer is etiologically and geneticallyheterogeneous. Important genetic factors have been indicated byfamilial occurrence and bilateral involvement. Mutations at morethan one locus can be involved in different families or even in thesame case. Note=Mutations in BRCA1 are thought to be responsiblefor 45% of inherited breast cancer. Moreover, BRCA1 carriers have a4-fold increased risk of colon cancer, whereas male carriers face a3-fold increased risk of prostate cancer. Cells lacking BRCA1 showdefects in DNA repair by homologous recombination.
Defects in BRCA1 are a cause of susceptibility tofamilial breast-ovarian cancer type 1 (BROVCA1) [MIM:604370]. Acondition associated with familial predisposition to cancer of thebreast and ovaries. Characteristic features in affected familiesare an early age of onset of breast cancer (often before age 50),increased chance of bilateral cancers (cancer that develop in bothbreasts, or both ovaries, independently), frequent occurrence ofbreast cancer among men, increased incidence of tumors of otherspecific organs, such as the prostate. Note=Mutations in BRCA1 arethought to be responsible for more than 80% of inheritedbreast-ovarian cancer.
Defects in BRCA1 are a cause of susceptibility to ovariancancer (OC) [MIM:167000]. The term ovarian cancer definesmalignancies originating from ovarian tissue. Although manyhistologic types of ovarian tumors have been described, epithelialovarian carcinoma is the most common form. Ovarian cancers areoften asymptomatic and the recognized signs and symptoms, even oflate-stage disease, are vague. Consequently, most patients arediagnosed with advanced disease.
Defects in BRCA1 are a cause of susceptibility topancreatic cancer type 4 (PNCA4) 

Contains 2 BRCT domains. 
Contains 1 RING-type zinc finger.

Database links:

Entrez Gene: 672 Human

Omim: 113705 Human

SwissProt: P38398 Human

Unigene: 194143 Human

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications

该基因编码一种核***蛋白,在维持基因组稳定性方面起作用,并且它还起肿瘤抑制物的作用。该编码蛋白与其他肿瘤抑制因子、DNA损伤传感器和信号转换器结合形成称为BRCA1相关基因组监测复合物(BASC)的大型多亚单位蛋白复合物。该基因产物与RNA聚合酶II结合,并通过C端结构域与组蛋白脱乙酰酶复合物相互作用。因此,该蛋白在转录、双链断裂的DNA修复和重组中起作用。该基因的突变导致大约40%的遗传性乳腺癌和80%以上的遗传性乳腺癌和卵巢癌。选择性剪接在调节该基因的亚细胞定位和生理功能中发挥作用。许多可选择的剪接转录体变异体,其中一些是疾病相关的突变,已经被描述用于该基因,但是仅描述了这些变异体中的一些的全长性质。一个相关的假基因,也位于17号染色体上,已经被鉴定出来。[ RefSeq,2009年5月提供]。






资料: 需要 不需要
报价: 需要 不需要